tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Curis files to sell 107.71M shares of common stock for holders
PremiumThe FlyCuris files to sell 107.71M shares of common stock for holders
1M ago
Curis Regains Nasdaq Compliance, Remains Under Monitoring Period
Premium
Company Announcements
Curis Regains Nasdaq Compliance, Remains Under Monitoring Period
1M ago
Curis Targets BTKi-Exposed CLL With New Emavusertib Combo Trial: What Investors Should Watch
Premium
Company Announcements
Curis Targets BTKi-Exposed CLL With New Emavusertib Combo Trial: What Investors Should Watch
2M ago
Promising Early Data from Curis’s Emavusertib Study Supports Buy Rating
PremiumRatingsPromising Early Data from Curis’s Emavusertib Study Supports Buy Rating
3M ago
Curis’s Strategic Clinical Advancements and Promising Data Drive Buy Rating
Premium
Ratings
Curis’s Strategic Clinical Advancements and Promising Data Drive Buy Rating
4M ago
Curis Inc. Earnings Call: Clinical Progress and Financial Gains
Premium
Company Announcements
Curis Inc. Earnings Call: Clinical Progress and Financial Gains
4M ago
CRIS Earnings this Week: How Will it Perform?
PremiumPre-EarningsCRIS Earnings this Week: How Will it Perform?
5M ago
Curis Inc.’s Promising Study on Emavusertib for AML and MDS: A Potential Game-Changer
Premium
Company Announcements
Curis Inc.’s Promising Study on Emavusertib for AML and MDS: A Potential Game-Changer
5M ago
Curis Inc. Advances Lymphoma Treatment with Emavusertib Study
Premium
Company Announcements
Curis Inc. Advances Lymphoma Treatment with Emavusertib Study
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100